Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection

Documenti analoghi

• Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir
  di: Derek Hansen, et al.
  Pubblicazione: (2025-05-01)
• Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm
  di: Arpa Hudait, et al.
  Pubblicazione: (2026-07-01)
• Lenacapavir-induced capsid damage uncovers HIV-1 genomes emanating from nuclear speckles
  di: Thorsten G Müller, et al.
  Pubblicazione: (2025-12-01)
• Lack of Resistance Mutations to the Novel HIV-1 Capsid Inhibitor Lenacapavir Among People Living with HIV in Guangdong, China
  di: Lin Y, et al.
  Pubblicazione: (2024-10-01)
• Genetic Diversity in the Capsid Protein-Coding Region of HIV-1 Circulating in Benguela, Angola: Implications for Primary Resistance to the Novel Capsid Inhibitor Lenacapavir
  di: Gonçalo Queirós, et al.
  Pubblicazione: (2025-05-01)